^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Acceptable Recurrence Therapies for Epithelial Ovarian (including LCOC)/Fallopian Tube/Primary Peritoneal Cancer….Recurrence Therapy for Platinum-Resistant Disease….Preferred Regimens...Targeted Therapy added: Mirvetuximab soravtansine-gynx (for FRα expressing tumors).
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Excerpt:
...Patients must provide an archival tumor tissue block or slides, or undergo procedure to obtain a new biopsy using a low-risk, medically routine procedure for immunohistochemistry (IHC) confirmation of FRα positivity; FRα-expressing tumors will be defined and classified by the Ventana FOLR1 Assay into low, medium, and high expressions defined as 25%-49%, 50%-74%, and ≥ 75% of tumor cells with PS2+ staining intensity, respectively....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

Excerpt:
...Patients must be willing to provide an archival tumor tissue block or slides, or must undergo a procedure to obtain a new biopsy using a low-risk, medically routine procedure for IHC confirmation of high FRα expression (reported as "positive") as defined by the Ventana FOLR1 Assay....
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Excerpt:
...- Patient's tumor must be positive for FRα expression as defined by a score of PS2+ intensity in >75% of cells...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Excerpt:
...Patient's tumor must be positive for FRα expression as defined by the Ventana FOLR1 (FOLR-2.1) CDx assay 7....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

c Un estudio para probar mirvetuximab soravtansina en mujeres con cánceres epiteliales de ovario, peritoneales primarios o de trompa de Falopio sensibles al platino.

Excerpt:
...Patient's tumor must be positive for FRα expression as defined by the Ventana FOLR1 Assay9. ...